2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
69
Breast Neoplasms
52
Carcinoma, Non-Small-Cell Lung
29
Neoplasms
27
Myelodysplastic Syndromes
27
Advanced Solid Tumors
27
Advanced Solid Tumor
26
Prostatic Neoplasms
24
Stomach Neoplasms
19
Recurrence
19
Multiple Myeloma
19
Neoplasm Metastasis
18
Carcinoma, Hepatocellular
18
Lung Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
14
Uterine Cervical Neoplasms
13
Solid Tumor
13
Sarcoma
13
Melanoma
13
Leukemia, Myelomonocytic, Chronic
13
Colorectal Neoplasms
12
Triple Negative Breast Neoplasms
10
Small Cell Lung Carcinoma
10
Lymphoma, Large B-Cell, Diffuse
10
Esophageal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Myeloproliferative Disorders
8
Lymphoma, Non-Hodgkin
8
Lymphoma, B-Cell
7
Interventions
human papillomavirus vaccine, L1 type 16, 18
40
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
32
Papillomavirus Vaccines
24
Human Papillomavirus Recombinant Vaccine nonavalent
12
Vaccines
11
Blood Specimen Collection
10
Data Collection
9
Colposcopy
9
Human Papillomavirus DNA Tests
8
Specimen Handling
7
Radiotherapy, Intensity-Modulated
7
Cisplatin
7
Surveys and Questionnaires
6
Educational Status
6
Early Intervention, Educational
6
Carboplatin
6
Vaginal Smears
5
Vaccines, Synthetic
5
Methods
5
Engerix-B
4
fludarabine
3
epigallocatechin gallate
3
artesunic acid
3
artemisinin
3
Watchful Waiting
3
Polymerase Chain Reaction
3
Patient Navigation
3
Paclitaxel
3
Observation
3
Mass Screening
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Papillomavirus Infections
×
Injections
×
Clear all
NCT04199689
2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
6,033 enrolled